KMT2D and breast cancer: While there is not enough scientific evidence to relate these alterations to endocrine therapy sensitivity, our group demonstrated that loss of KMT2D sensitizes breast cancer further to PI3K inhibitors through the downregulation of the ER signaling cascade (43).